Recent interventions in a study on rodents revealed T2 3,5-diiodo-L-thyronine as a metabolically active iodothyronine affecting energy and lipid metabolism without thyromimetic side effects typically associated with T3 administration. Accordingly, T2 3,5-diiodo-L-thyronine has been proposed as a potential hypolipidemic agent for treatment of obesity and hepatic steatosis. Data from the study indicate metabolic changes induced by T2 3,5-diiodo-L-thyronine in diet-induced obese male mice, which resulted in decrease of body fat mass and hepatic lipid content. Each T2 3,5-diiodo-L-thyronine tablet contains 100mcg.
|Molar Mass||525,077 g/mol|
|IUPAC Name||(2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid|
By completing and paying for your order, you agree to our Terms and Conditions. Customer satisfaction is our number one priority, if you are not 100% satisfied with the product you received, please contact us at firstname.lastname@example.org
We are not affiliated, associated, authorized, endorsed by, or in any way officially connected with SARMScentral.org, or any of its subsidiaries or its affiliates.